hello world
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.
Stocks in play: Resverlogix Corp.
Today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells" in the journal Biomedicines. Resverlogix Corp. shares T.RVX are trading unchanged at $0.07.
